Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

Summary

The purpose of this study is to determine whether 40 mg octreotide long-acting release intramuscular every 28 days is effective in the treatment of patients with refractory anemia due to gastrointestinal angiodysplasias. We hypothesize that octreotide is effective in reducing the transfusion requirements (consisting of red blood cell transfusions and intravenous iron infusions) of patients with angiodysplasia-related anemia.

Conditions

• Angiodysplasia
• Vascular Malformations
• Gastrointestinal Hemorrhage
• Anemia

Interventions

DRUG

Octreotide

Two injections of 20 mg will be given monthly.

Sponsors & Collaborators

• Jeroen Bosch Ziekenhuis

  collaborator OTHER

• Elisabeth-TweeSteden Ziekenhuis

  collaborator OTHER

• Catharina Ziekenhuis Eindhoven

  collaborator OTHER

• Bernhoven Hospital

  collaborator OTHER

• Tjongerschans hospital

  collaborator UNKNOWN

• Gelre Hospitals

  collaborator OTHER

• Maasstad Hospital

  collaborator OTHER

• Reinier de Graaf Groep

  collaborator OTHER

• University Medical Center Groningen

  collaborator OTHER

• Rijnstate Hospital

  collaborator OTHER

• St. Antonius Hospital

  collaborator OTHER

• Radboud University Medical Center

  lead OTHER

Principal Investigators

• Joost Drenth, MD. PhD · Radboud University Medical Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-09-30

Primary Completion

2022-07-31

Completion

2023-05-31

Countries

• Netherlands

Study Locations